The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology
Abstract
TP53 mutation is one of the most common genetic changes in hepatocellular carcinoma (HCC). It is of great clinical significance to tailor specialized prognostication approach and to explore more therapeutic options for TP53-mutant HCCs. In this study, a total of 1135 HCC patients were retrospectively analyzed. We developed a random forest-based prediction model to estimate TP53 mutational status, tackling the problem of limited sample size in TP53-mutant HCCs. A multi-step process was performed to develop robust poor prognosis-associated signature (PPS). Compared with previous established population-based signatures, PPS manifested superior ability to predict survival in TP53-mutant patients. After in silico screening of 2249 drug targets and 1770 compounds, we found that three targets (CANT1, CBFB and PKM) and two agents (irinotecan and YM-155) might have potential therapeutic implications in high-PPS patients. The results of drug targets prediction and compounds prediction complemented each other, presenting a comprehensive view of potential treatment strategy. Overall, our study has not only provided new insights into personalized prognostication approaches, but also thrown light on integrating tailored risk stratification with precision therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Next-generation characterization of the Cancer Cell Line Encyclopedia
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1186-3 · Cited by 3,394
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Self-citationPyruvate kinase type M2 and its role in tumor growth and spreading
Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.009 · Cited by 812
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Fujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H., Taniguchi, H., Kawakami, Y., Ueno, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3547 · Cited by 689
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1607-3 · Cited by 427
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.022 · Cited by 380
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality
Jerby-Arnon, L., Pfetzer, N., Waldman, Y. Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P. A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.027 · Cited by 284
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.038 · Cited by 279
Self-citationNo evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
Bluemlein, K., Grüning, N.-M., Feichtinger, R. G., Lehrach, H., Kofler, B., & Ralser, M. (2011) · Oncotarget · doi:10.18632/oncotarget.278 · Cited by 253
Giaccone, G., Zatloukal, P., Roubec, J., Floor, K., Musil, J., Kuta, M., van Klaveren, R. J., Chaudhary, S., Gunther, A., & Shamsili, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1862 · Cited by 245
Metabolism‐associated molecular classification of hepatocellular carcinoma
Yang, C., Huang, X., Liu, Z., Qin, W., & Wang, C. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12639 · Cited by 189
Self-citationLong, J., Zhang, L., Wan, X., Lin, J., Bai, Y., Xu, W., Xiong, J., & Zhao, H. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13863 · Cited by 174
Désert, R., Rohart, F., Canal, F., Sicard, M., Desille, M., Renaud, S., Turlin, B., Bellaud, P., Perret, C., Clément, B., et al. (2017) · Hepatology · doi:10.1002/hep.29254 · Cited by 148
Liu, J., Ma, Q., Zhang, M., Wang, X., Zhang, D., Li, W., Wang, F., & Wu, E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.001 · Cited by 130
Liu, G., Xie, W., Zhang, C., & Xu, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29081 · Cited by 110
Wang, Q., Chen, Z., Diao, X., & Huang, S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.007 · Cited by 89
Malik, N., Yan, H., Moshkovich, N., Palangat, M., Yang, H. H., Sanchez, V. C., Cai, Z., Peat, T. J., Jiang, S., Liu, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10102-6 · Cited by 88
Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner, D., Mesterharm, J., Akrivakis, C., Geppert, R., Petrides, P. E., Wernecke, K.-D., & Possinger, K. (2000) · PubMed · Cited by 84
A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma
O'Reilly, E. M., Stuart, K. E., Sanz-Altamira, P. M., Schwartz, G. K., Steger, C., Raeburn, L., Kemeny, N. E., Kelsen, D. P., & Saltz, L. B. (2001) · Cancer · Cited by 83
Li, B., Feng, W., Luo, O., Xu, T., Cao, Y., Wu, H., Yu, D., & Ding, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-04811-5 · Cited by 83
Boige, V., Taïeb, J., Hebbar, M., Malka, D., de Baère, T., Hannoun, L., Magherini, E., Mignard, D., Poynard, T., & Ducreux, M. P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.034 · Cited by 64
Yan, Y., Lu, Y. J., Mao, K., Zhang, M., Liu, H., Zhou, Q., Lin, J., Zhang, J., Wang, J., & Xiao, Z. (2019) · Hepatology International · doi:10.1007/s12072-019-09962-3 · Cited by 62
Takeba, Y., Kumai, T., Matsumoto, N., Nakaya, S., Tsuzuki, Y., Yanagida, Y., & Kobayashi, S. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0070442 · Cited by 57
Somatic selection distinguishes oncogenes and tumor suppressor genes
Chandrashekar, P. B., Ahmadinejad, N., Wang, J., Sekulić, A., Egan, J. B., Asmann, Y. W., Kumar, S., Maley, C. C., & Liu, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz851 · Cited by 48
PKM2 Knockdown Induces Autophagic Cell Death via AKT/mTOR Pathway in Human Prostate Cancer Cells
Dey, P. K., Kundu, A. B., Sachan, R., Park, J. H., Ahn, M. Y., Yoon, K., Lee, J., Kim, N. D., Kim, I. S., Lee, B. M., et al. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000107 · Cited by 45
Xu, L. L., Zhu, Y., Shao, J., Chen, M., Yan, H., Li, G., Zhu, Y., Xu, Z., Yang, B., Luo, P., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.55 · Cited by 37
Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression
Edwards, L., Gupta, R., & Filipp, F. V. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0403 · Cited by 35
Pyruvate kinase M2 contributes to cell growth in gastric cancer via aerobic glycolysis
Li, H., Xu, H., Xing, R., Pan, Y., Li, W., Cui, J., & Lu, Y. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.001 · Cited by 26
Davis, J. N., Rogers, D. L., Adams, L. K., Yong, T., Jung, J. S., Cheng, B., Fennell, K. A., Borazanci, E. H., Moustafa, Y. W., Sun, A., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22298 · Cited by 25
PKM2 Knockdown Induces Autophagic Cell Death via the AKT/mTOR Pathway in Human Prostate Cancer CellsPreprint
Dey, P. K., Kundu, A. B., Sachan, R., Park, J., Ahn, M. Y., Yoon, K., Lee, J., Kim, N. D., Kim, I. S., Lee, B. M., et al. (2019) · Preprints.org · doi:10.20944/preprints201901.0018.v1 · Cited by 25
Xia, H., Chen, J., Shi, M., Deivasigamani, A., Ooi, L. L., & Hui, K. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3337 · Cited by 23
Self-citationSaida, S., Zhen, T., Kim, E., Yu, K., Lopez, G., McReynolds, L. J., & Liu, P. (2019) · Leukemia · doi:10.1038/s41375-019-0605-7 · Cited by 20
Cited by
Lu, J., Duan, Y., Liu, P., He, X., Yang, Y., Zhang, R., & Weng, L. (2023) · The Journal of Pathology · doi:10.1002/path.6015 · Cited by 6
Metadata
- Authors
- Yang, C., Huang, X., Li, Y., Chen, J., Lv, Y., & Dai, S.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-13
- Volume
- 22
- Issue
- 3
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W3049314860
- Cited by
- 269
- References
- 42
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.